· 2 min read
Yeast Study Compares How Two Bleomycin Drugs Break DNA Strands
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer
· 2 min read
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Based on the PubMed abstract — the full text of this paper was not freely available.
Moore reported in Biochemistry (1990) that two closely related forms of the anticancer drug bleomycin, called A2 and B2, differ sharply in how many breaks they cause in DNA, and that this difference—not drug concentration alone—explains how much they kill cells.
The work used yeast (Saccharomyces cerevisiae) cells, some normal and some genetically altered to lack a working DNA ligase, the enzyme that reseals broken DNA strands. By labeling DNA with radioactive tracers and spinning it through a calibrated gradient, Moore counted the breaks each drug produced at various doses. Breaks rose roughly in step with drug dose, and surprisingly, cells with and without working ligase accumulated similar numbers of breaks, suggesting that under these conditions repair was not actively removing damage as it occurred. Bleomycin B2 caused considerably more breaks than bleomycin A2, even though the two molecules differ only in one chemical group.
This is laboratory chemistry and yeast genetics, not a human or animal study, and it says nothing about skin, wound healing, or therapeutic use of DNA fragments. It cannot show how these findings apply outside this specific experimental system.
Our reflection
This paper belongs to the decades of basic nucleic-acid chemistry that mapped, piece by piece, how DNA can be cut, repaired and studied at the molecular level—groundwork that today's polydeoxyribonucleotide research builds on. It has no direct bearing on skin or regenerative applications, but at Havdis, we see value in understanding this long history of rigorous DNA science.
Source
Moore CW (1990). Biochemistry.
Read the paper on PubMedDOI: 10.1021/bi00457a033
This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.
Related
A 1993 European Journal of Pharmacology study on how defibrotide, a polydeoxyribonucleotide, binds adenosine A1 and A2 receptors in lab experiments.
Read more →1992 Life Sciences study on how defibrotide, a PDRN sodium salt, may fight blood clots via free-radical scavenging and immune cell modulation.
Read more →1992 Thrombosis Research study: defibrotide limited calcium overload and arrhythmia in low-flow perfused rabbit hearts via prostaglandin signaling.
Read more →